Hims & Hers Turns AI and Global Scale Into a New Kind of Health Platform
Q2 2026 results show a reaccelerating domestic business, a peptide bet on hold, and an AI-native experience that cuts costs and deepens retention.
HIMS · Earnings Call · 2026-08-10
Proof, Not Just Promise
Hims & Hers Health reported a quarter that management framed as “proof” — Andrew Dudum, Co-Founder and Chief Executive Officer · 2026-08-10 — proof that a health experience can scale globally while remaining profitable. Revenue grew nearly 40% year-over-year to $753M, subscribers hit nearly 3M, and international revenue surged 17-fold to $131M, largely driven by the Eucalyptus acquisition. But the real story is what CEO Andrew Dudum called “a first-of-its-kind health experience” — Andrew Dudum, Co-Founder and Chief Executive Officer · 2026-08-10 — one built on AI, vertical integration, and a widening moat in specialty categories.
We're playing offense, and we have the balance sheet and cost structure to sustain it in a way others cannot.
The pivot toward branded weight-loss products, which began in March, has reaccelerated domestic growth to 16% in the quarter. CFO Yemi Okupe noted that the shift to a monthly cadence for branded offerings is starting to compound as cohorts stack, and he expects that acceleration to continue into the back half. The company raised full-year revenue guidance to $3.1–$3.3B, implying 32–41% growth, while keeping adjusted EBITDA at $275–$325M.
AI as Load‑Bearing Infrastructure
Chief Technology Officer Mo ElShenawy made the most striking claim: “We are making AI load-bearing, not decorative.” — Mohamed ElShenawy, Chief Technology Officer · 2026-08-10 The new AI‑native care experience, launched for Hers weight-loss customers in July, is already producing tangible results — customers send 3x more messages, AI answers 80% of questions, and nonclinical support tasks have dropped nearly 50%. These early wins are translating into meaningful cost savings. “Operations and support delivered three points of sequential leverage in the second quarter,” — Yemi Okupe, Chief Financial Officer · 2026-08-10 Yemi said, pointing directly to AI‑driven efficiencies.
The company is doubling down on AI infrastructure, planning an R&D lab in Menlo Park and hiring more AI talent. Management believes the closed‑loop data from millions of subscribers gives them an edge that pure‑play AI chatbots cannot match. The result is a flywheel: better engagement → better retention → more data → better personalization → lower acquisition costs. This is not just an efficiency story; it is a customer‑lifetime‑value story.
Peptides: The Next Frontier on Hold
Hims & Hers has positioned itself to be a leader in the emerging peptide category, but it is deliberately waiting for final FDA rulemaking. As Andrew Dudum put it, “We are currently developing a best-in-class peptides experience, including U.S.-manufactured products, clinically led guidance and ongoing blood testing.” — Andrew Dudum, Co-Founder and Chief Executive Officer · 2026-08-10 The company has already begun validation and stability testing on APIs for the six peptides recommended by the PCAC, and it has a plan to offer already‑allowed peptides like sermorelin, glutathione, and NAD+ by year‑end. This is consistent with the philosophy Andrew articulated in a prior call: “I've never believed strategically it was critical for us to be first to market... not necessarily first but best.” — Maria Ripps, Analyst · 2026-05-11 The infrastructure — over 1 million square feet of pharmacy and lab space — is already in place, and the company is betting that when the regulatory door opens, it will be the safest and most trusted entry point.
Global Scale and the Novo Nordisk Tailwind
The Eucalyptus acquisition has made Hims & Hers the leading global consumer health platform in several markets. The U.K., Australia, and Germany are each annualizing over $100M, and the company expects international revenue of at least $600M in 2026. The Novo Nordisk partnership continues to be a powerful driver, expanding access to branded weight-loss treatments and opening up data-sharing opportunities. This aligns with the earlier vision expressed by Andrew in a prior call: “We believe there's a really durable weight business even if you think [of] a draconian scenario” — Andrew Dudum, Chief Executive Officer · 2026-02-23 — a comment that now looks prescient given the successful pivot.
Total revenue has grown from $608M in 2026Q1 to $753M in Q2, up 40% YoY. However, gross margin has compressed significantly to 64%, down 6 points sequentially, as the mix shifts toward branded products and international. This is a deliberate trade-off; management expects margins to remain below historical levels but sees unit economics improving with scale. Gross margin has fallen from 82.4% peak in 2024Q1 to 65.2% in 2026Q1 (latest reported) — a 17‑point decline. Yet free cash flow is expected to resume in H2, and the balance sheet is strong with $840M cash after the Eucalyptus spend.
What Changed, and Why It Matters
The biggest change is that Hims & Hers has moved from a single‑condition telehealth player to a full‑stack, AI‑powered consumer health platform with global reach. The company is no longer just a distributor of GLP‑1s; it is building an ecosystem that includes diagnostics, labs, specialty care, and a peptide pipeline. The consumer health platform is becoming the front door for innovative therapies — a role that major pharma partners are increasingly recognizing. The key risks remain regulatory (peptides, FTC lawsuit) and margin pressure, but the market has rewarded the pivot: the stock is up ~74% over the last 90 days.
Hims & Hers is executing on a vision that few consumer health companies can match. The combination of AI-native care, vertical integration, and international scale is creating a structural advantage that is hard to replicate. As Andrew said, “We are building something entirely new, and it is increasingly difficult to replicate.” — Andrew Dudum, Co-Founder and Chief Executive Officer · 2026-08-10 For investors, the question is not whether the company can grow, but whether it can sustain this momentum while navigating the regulatory and competitive landscape. The early evidence suggests it can.